Deborah Brown - Oncolytics Biotech Independent Director
| ONC Stock | CAD 1.33 0.02 1.53% |
Director
Ms. Deborah M. Brown, B.Sc., M.B.A., is Director of the Company. In addition to being a Management Consultant since 2014, Ms. Brown is currently a Managing Partner at Accelera Canada, a specialty consultancy firm that assists emerging biopharma ventures inthe United States and Europe with the development and implementation of Canadian market strategies. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company U.S. operations, and President and Managing Director of the company Canadian operations. In 2012, Ms. Brown was Chair of the National Pharmaceutical Organization and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA since 2017.
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5 |
| Phone | 403 670 7377 |
| Web | https://www.oncolyticsbiotech.com |
Oncolytics Biotech Management Efficiency
The company has return on total asset (ROA) of (0.7133) % which means that it has lost $0.7133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.3822) %, meaning that it generated substantial loss on money invested by shareholders. Oncolytics Biotech's management efficiency ratios could be used to measure how well Oncolytics Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to drop to -1.03. At this time, Oncolytics Biotech's Other Current Assets are very stable compared to the past year. As of the 27th of November 2024, Other Assets is likely to grow to 1.05, while Total Assets are likely to drop about 30.5 M.Management Performance
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.71 |
Oncolytics Biotech Leadership Team
Elected by the shareholders, the Oncolytics Biotech's board of directors comprises two types of representatives: Oncolytics Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncolytics. The board's role is to monitor Oncolytics Biotech's management team and ensure that shareholders' interests are well served. Oncolytics Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncolytics Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ger Amersfoort, Independent Director | ||
| FCA FCA, Consultant | ||
| Dr MBA, CEO President | ||
| Wayne Pisano, Independent Chairman of the Board | ||
| Jon Patton, Director Communication | ||
| Wayne MBA, Interim Board | ||
| Andrew Guttadauro, Global Head of Business Development and Presidentident, Oncolytics Biotech (U.S.) Inc. | ||
| Grey Wilkinson, Scientist Medicine | ||
| Andres Gutierrez, Chief Medical Officer | ||
| BBA FCA, Consultant | ||
| Matthew Coffey, President, Chief Executive Officer, Chief Operating Officer, Director | ||
| William Rice, Independent Director | ||
| Allison Hagerman, Vice President - Product Development | ||
| Edwin Levy, Independent Director | ||
| Alan Tuchman, Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs | ||
| Amy Levin, Vice Operations | ||
| Kirk Look, Chief Financial Officer | ||
| Rita Laeufle, Chief Medical Officer | ||
| FACP FACP, Consultant | ||
| CA CA, Chief Officer | ||
| Linda Hohol, Independent Director | ||
| Deborah Brown, Independent Director | ||
| J Lievonen, Director | ||
| RN BSN, Vice Operations | ||
| Bernd Seizinger, Independent Director | ||
| PMP PEng, Vice Development | ||
| Angela Holtham, Independent Director | ||
| BBA CM, Consultant | ||
| Mary Dillahunty, Vice President - Intellectual Property | ||
| Leonard Kruimer, Independent Director | ||
| Michael Moore, Vice President Investor Relations & Corporate Communications | ||
| George Gill, Senior Vice President - Regulatory Affairs & Chief Safety Officer |
Oncolytics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncolytics Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 82.43 M | ||||
| Shares Outstanding | 77.07 M | ||||
| Shares Owned By Insiders | 3.81 % | ||||
| Shares Owned By Institutions | 1.76 % | ||||
| Number Of Shares Shorted | 439.37 K | ||||
| Price To Earning | (4.18) X | ||||
| Price To Book | 11.15 X | ||||
| EBITDA | (33.71 M) |
Pair Trading with Oncolytics Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.
The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..